职称：副教授
学历：博士
E-mail：20250086@hbut.edu.cn
研究方向：PROTAC药物的开发及生物活性研究
学习及工作经历：
2013.09-2017.06 武汉大学 药学院 学士
2017.09-2022.06 武汉大学 药学院 博士（导师：周海兵教授、董春娥教授）
2022.07-2025.08 武汉大学中南医院 博士后
2025.09-至今 湖北工业大学 生命科学与健康工程学院 副教授
研究课题：
（1）国家自然科学基金青年C类项目（2026.01-2028.12）：协同靶向肿瘤干细胞策略的STAT3-ERα双靶点抑制剂的构建及抗内分泌耐药乳腺癌研究，主持。
（2）湖北省自然科学基金青年项目（2025.03-2027.02）：靶向XPO1的新型PROTAC分子的构建及抗耐药多发性骨髓瘤活性研究，主持。
（3）国家自然科学基金面上项目（2022.01-2025.12）：基于靶向雌激素受体β降解策略的小分子降解剂的设计合成及抗肺癌活性研究，参与。
（4）国家自然科学基金面上项目（2021.01-2024.12）：靶向雌激素受体降解策略的双功能小分子药物发现及对受体突变耐药性乳腺癌的治疗研究，参与。
研究成果：
（1）Baohua Xie#, Zhinang Yin#, Zhiye Hu#, Junhui Lv, Chuanqian Du, Xiangping Deng, Yuan Huang, Qiuzi Li, Jian Huang*, Kaiwei Liang*, Hai-Bing Zhou*, Chune Dong*. Discovery of a novel class of PROTACs as potent and selective estrogen receptor α degraders to overcome endocrine-resistant breast cancer in vitro and in vivo. Journal of Medicinal Chemistry 2023, 66 (10), 6631-6651.
（2）Baohua Xie#, Bin Xu#, Lilan Xin, Yizhou Wei, Xinyi Guo, Chune Dong*. Discovery of estrogen receptor α targeting caged hypoxia-responsive PROTACs with an inherent bicyclic skeleton for breast cancer treatment. Bioorganic Chemistry 2023, 137, 106590.
（3）Baohua Xie#, Qiuyu Meng#, Huiguang Yu, Kang Shen, Yan Cheng, Chune Dong*, Hai-Bing Zhou*. Estrogen receptor β-targeted hypoxia-responsive near-infrared fluorescence probes for prostate cancer study. European Journal of Medicinal Chemistry 2022, 238, 114506.
（4）Yunchong Meng#, Xiaofei Deng#, Baohua Xie#, Wei Lin, Na Wang, Xiaojun Wang, Shihao Wu, Chune Dong*, Yongde Liao*, Hai-Bing Zhou*. Targeted degradation of estrogen receptor β to overcome Osimertinib resistance in non-small cell lung carcinoma. Bioorganic Chemistry 2026, 168, 109374.
（5）Yubo Wang#, Baohua Xie#, Xiaofei Deng, Chune Dong*, Hai-Bing Zhou*. Targeted degradation of the estrogen receptor α through unconventional coactivator binding site (CBS). Journal of Medicinal Chemistry 2025, 68 (13), 13640-13660.
（6）Yihe Wu#, Baohua Xie#, Jinsen Liang#, Dongmei Wei, Yubo Wang, Yudong Yin, Xiaofei Deng, Chao Wang, Jian Ni, Lanxin Yang, Chune Dong*, Xin Han*, Hai-Bing Zhou*. Kill two birds with one stone: An efficient and potent AR CBS-targeted degrader reverses breast cancer resistance via concurrent AR degradation and ERα transcriptional suppression. Journal of Medicinal Chemistry 2025, 68 (22), 24136-24167.
（7）Xiangping Deng#, Baohua Xie#, Qiuzi Li#, Yuan Xiao, Zhiye Hu, Xiaofei Deng, Pingping Fang*, Chune Dong*, Hai-Bing Zhou*, Jian Huang*. Discovery of novel bicyclic phenylselenyl-containing hybrids: an orally bioavailable, potential and multi-acting class of estrogen receptor modulators against endocrine-resistant breast cancer. Journal of Medicinal Chemistry 2022, 65 (11), 7993-8010.
（8）Qiuyu Meng#, Baohua Xie#, Huiguang Yu, Kang Shen, Xiangping Deng, Hai-Bing Zhou*, Chune Dong*. Estrogen receptor β targeted near-infrared inherently fluorescent probe: a potent tool for estrogen receptor β research. ACS Sensors 2022, 7 (1), 109-115.
